Germany, Sept. 4 -- Germany based Biogen GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products - Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Natalizumab (exclusively in the Dafo injection solution, ATC L04AA23 for the period 010924 - 310826 . The value of the contract is not disclosed .
Published by HT Digital Content Services with permission from Pivotal Sources....